<pmc-articleset>
  <article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4">
    <!--The publisher of this article does not allow downloading of the full text in XML form.-->
    <front>
      <journal-meta>
        <journal-id journal-id-type="nlm-ta">Nat Cancer</journal-id>
        <journal-id journal-id-type="iso-abbrev">Nat Cancer</journal-id>
        <journal-id journal-id-type="pmc-domain-id">319</journal-id>
        <journal-id journal-id-type="pmc-domain">nihpa</journal-id>
        <journal-title-group>
          <journal-title>Nature cancer</journal-title>
        </journal-title-group>
        <issn pub-type="epub">2662-1347</issn>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-is-collection-domain</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-collection-title</meta-name>
            <meta-value>NIHPA Author Manuscripts</meta-value>
          </custom-meta>
        </custom-meta-group>
      </journal-meta>
      <article-meta>
        <article-id pub-id-type="pmcid">PMC7450824</article-id>
        <article-id pub-id-type="pmcid-ver">PMC7450824.1</article-id>
        <article-id pub-id-type="pmcaid">7450824</article-id>
        <article-id pub-id-type="pmcaiid">7450824</article-id>
        <article-id pub-id-type="manuscript-id">NIHMS1595849</article-id>
        <article-id pub-id-type="pmid">32864625</article-id>
        <article-id pub-id-type="doi">10.1038/s43018-020-0047-1</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHMS1595849</article-id>
        <article-id pub-id-type="manuscript-id-alternative">NIHPA1595849</article-id>
        <article-version article-version-type="pmc-version">1</article-version>
        <article-categories>
          <subj-group subj-group-type="heading">
            <subject>Article</subject>
          </subj-group>
        </article-categories>
        <title-group>
          <article-title>Alterations in <italic toggle="yes">PTEN</italic> and <italic toggle="yes">ESR1</italic> promote clinical resistance to alpelisib plus aromatase inhibitors</article-title>
        </title-group>
        <contrib-group>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Razavi</surname>
              <given-names initials="P">Pedram</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref rid="CR1" ref-type="corresp">*</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Dickler</surname>
              <given-names initials="MN">Maura N.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="author-notes" rid="FN1">#</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shah</surname>
              <given-names initials="PD">Payal D.</given-names>
            </name>
            <xref ref-type="aff" rid="A4">4</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Toy</surname>
              <given-names initials="W">Weiyi</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brown</surname>
              <given-names initials="DN">David N.</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Won</surname>
              <given-names initials="HH">Helen H.</given-names>
            </name>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Li</surname>
              <given-names initials="BT">Bob T.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Shen</surname>
              <given-names initials="R">Ronglai</given-names>
            </name>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Vasan</surname>
              <given-names initials="N">Neil</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Modi</surname>
              <given-names initials="S">Shanu</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Jhaveri</surname>
              <given-names initials="K">Komal</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Caravella</surname>
              <given-names initials="BA">Betty Ann</given-names>
            </name>
            <xref ref-type="aff" rid="A8">8</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Patil</surname>
              <given-names initials="S">Sujata</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A7">7</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Selenica</surname>
              <given-names initials="P">Pier</given-names>
            </name>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Zamora</surname>
              <given-names initials="S">Stephen</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Cowan</surname>
              <given-names initials="AM">Aimee M.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Comen</surname>
              <given-names initials="E">Elizabeth</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Singh</surname>
              <given-names initials="A">Andy</given-names>
            </name>
            <xref ref-type="aff" rid="A9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Covey</surname>
              <given-names initials="A">Anne</given-names>
            </name>
            <xref ref-type="aff" rid="A8">8</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Berger</surname>
              <given-names initials="MF">Michael F.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A5">5</xref>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Hudis</surname>
              <given-names initials="CA">Clifford A.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A10">10</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Norton</surname>
              <given-names initials="L">Larry</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Nagy</surname>
              <given-names initials="RJ">Rebecca J.</given-names>
            </name>
            <xref ref-type="aff" rid="A9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Odegaard</surname>
              <given-names initials="JI">Justin I.</given-names>
            </name>
            <xref ref-type="aff" rid="A9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lanman</surname>
              <given-names initials="RB">Richard B.</given-names>
            </name>
            <xref ref-type="aff" rid="A9">9</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Solit</surname>
              <given-names initials="DB">David B.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A6">6</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Robson</surname>
              <given-names initials="ME">Mark E.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Lacouture</surname>
              <given-names initials="ME">Mario E.</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Brogi</surname>
              <given-names initials="E">Edi</given-names>
            </name>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Reis-Filho</surname>
              <given-names initials="JS">Jorge S.</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Moynahan</surname>
              <given-names initials="ME">Mary Ellen</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A3">3</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Scaltriti</surname>
              <given-names initials="M">Maurizio</given-names>
            </name>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref ref-type="aff" rid="A5">5</xref>
          </contrib>
          <contrib contrib-type="author">
            <name name-style="western">
              <surname>Chandarlapaty</surname>
              <given-names initials="S">Sarat</given-names>
            </name>
            <xref ref-type="aff" rid="A1">1</xref>
            <xref ref-type="aff" rid="A2">2</xref>
            <xref ref-type="aff" rid="A3">3</xref>
            <xref rid="CR1" ref-type="corresp">*</xref>
          </contrib>
        </contrib-group>
        <aff id="A1"><label>1</label>Department of Medicine, MSKCC, New York, NY</aff>
        <aff id="A2"><label>2</label>Human Oncology and Pathogenesis Program, MSKCC, New York, NY</aff>
        <aff id="A3"><label>3</label>Weill Cornell Medical College, New York, NY</aff>
        <aff id="A4"><label>4</label>Department of Medicine, University of Pennsylvania, Philadelphia PA</aff>
        <aff id="A5"><label>5</label>Department of Pathology, MSKCC, New York, NY</aff>
        <aff id="A6"><label>6</label>Marie-Josée and Henry R. Kravis Center for Molecular Oncology, MSKCC, New York, NY</aff>
        <aff id="A7"><label>7</label>Department of Epidemiology and Biostatistics, MSKCC, New York, NY</aff>
        <aff id="A8"><label>8</label>Department of Radiology, MSKCC, New York, NY</aff>
        <aff id="A9"><label>9</label>Guardant Health, Inc., Redwood City, CA</aff>
        <aff id="A10"><label>10</label>American Society of Clinical Oncology, Alexandria, VA</aff>
        <author-notes>
          <fn fn-type="current-aff" id="FN1">
            <label>#</label>
            <p id="P1">Current affiliation: Eli Lilly, Indianapolis, IN</p>
          </fn>
          <fn fn-type="con" id="FN2">
            <p id="P2">Contributions</p>
            <p id="P3">Conceived the study: P.R., M.N.D., P.D.S., M.E.M., M.S., S.C.; Data acquisition: P.R., M.N.D., P.D.S., W.T., B.T.L., N.V., S.M., K.J., B.A.C., P.S., S.Z., A.C., E.C., S.M.S., A.C., M.F.B., R.J.N., J.I.O., R.B.L., D.B.S., M.E.L., E.B., M.E.M.; Data analysis and interpretation: P.R., D.N.B., H.H.W., R.S., S.P., A.S., R.J.N., J.I.O., J.S.R-F; Bioinformatics and genomic analysis: P.R., D.N.B., H.H.W., R.S., P.S., A.S., J.S.R-F; Manuscript first draft: P.R., M.N.D., P.D.S., M.E.M., S.C. wrote the manuscript with input from all authors. Manuscript review and approval: all authors.</p>
          </fn>
          <corresp id="CR1"><label>*</label>Correspondence to: <email>razavip@mskcc.org</email>, <email>chandars@mskcc.org</email></corresp>
          <fn fn-type="COI-statement" id="FN3">
            <p id="P62">Competing Interests</p>
            <p id="P63">P.R. reports consulting or advisory role for Novartis, AstraZeneca, Foundation Medicine, and institutional research support from Illumina and GRAIL; M.N.D. is an employee of Eli Lilly, P.D.S. reports consulting with Tmnity and research funding from AstraZeneca; B.T.L. reports consulting/advisory board for Genentech, ThermoFisher Scientific, Guardant Health, Hengrui Therapeutics, Mersana Therapeutics, Biosceptre Australia and institutional research support from Illumina, GRAIL, Genentech, AstraZeneca; N.V. reports consulting or advisory role for Novartis; K.J. reports consulting or advisory role for ADC Therapeutics; AstraZeneca; Jounce therapeutics; Novartis; Pfizer; Spectrum; Taiho, research funding from ADC Therapeutics (Inst); Clovis Oncology (Inst); Debio (Inst); Genentech (Inst); Novartis (Inst); Novita (Inst); Pfizer (Inst) and other relationship with Jounce Therapeutics; Novartis; Pfizer; Taiho; A.C. reports being an advisory board member for Accurate Medical a Stockholder for Amgen; L.N. reports honoraria from Advanced Breast Cancer 4 International Consensus Conference; Bluprint Oncology Concepts; Celgene; Context Therapeutics; MCI Breast Cancer Symposium, consulting or advisory role for Advanced Breast Cancer International Consensus Conference; Bluprint Oncology Concepts; Celgene; Context Therapeutics; MCI Breast Cancer Symposium and travel, accommodations, expenses from Advanced Breast Cancer International Consensus Conference; Celgene; MCI Breast Cancer Symposium; A.S., R.J.N., J.I.O., and R.B.L. are employees and stockholders of Guardant Health; M.E.R. reports honoraria from AstraZeneca, consulting or advisory role for AstraZeneca; McKesson; Merck; Pfizer, research funding from Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); Medivation (Inst); Myriad Genetics (Inst); Tesaro (Inst), and travel, accommodations, expenses from AstraZeneca; M.E.L. reports serving as a consultant or speaking for Legacy Healthcare Services, Adgero Bio, Amryt, Celldex, Debiopharm, Galderma, Johnson &amp; Johnson, Novocure, Lindi, Merck, Sharp and Dohme Corp, Helsinn Healthcare SA, Janssen Research &amp; Development LLC, Menlo Therapeutics, Novartis, Roche, AbbVie, Boehringer Ingelheim, Allergan, Amgen, E. R. Squibb &amp; Sons, LLC, EMD Serono, AstraZeneca, Genentech, Leo Pharma, Seattle Genetics, Bayer, Manner, SAS, Lutris, Pierre Fabre, Paxman Coolers, Adjucare, Dignitana, Biotechspert, Teva Mexico, Parexel, OnQuality, Novartis, Our Brain Bank, and Takeda Millenium; and receiving research funding from Veloce, US Biotest, Berg, BMS, Lutris, Paxman, and Novocure; J.S.R-F reports personal/consultancy fees from VolitionRx, Page.AI, Goldman Sachs, Grail, Ventana Medical Systems, Roche, Genentech and Invicro; D.B.S. received honoraria and consulted for Pfizer, Loxo, Vivideon, Illumina and Lilly Oncology; M.S. is in the Advisory Board of Bioscience Institute and Menarini Ricerche, received research funds from Puma Biotechnology, Daiichi Sankyo, Targimmune, Immunomedics and Menarini Ricerche, is a co-founder of Medendi Medical Travel and received honoraria from Menarini Ricerche and ADC; S.C. reports institutional research funding from Novartis, Eli Lilly, Sanofi, Daiichi Sankyo, Genentech and Ad hoc consulting for Novartis, Context Therapeutics, Sermonix, Eli Lilly, BMS, and Revolution Medicine. The other coauthors report no competing interests.</p>
          </fn>
        </author-notes>
        <pub-date pub-type="epub">
          <day>23</day>
          <month>3</month>
          <year>2020</year>
        </pub-date>
        <pub-date pub-type="ppub">
          <month>4</month>
          <year>2020</year>
        </pub-date>
        <volume>1</volume>
        <issue>4</issue>
        <issue-id pub-id-type="pmc-issue-id">364002</issue-id>
        <fpage>382</fpage>
        <lpage>393</lpage>
        <pub-history>
          <event event-type="nihms-submitted">
            <date>
              <day>23</day>
              <month>05</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-release">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-live">
            <date>
              <day>01</day>
              <month>10</month>
              <year>2020</year>
            </date>
          </event>
          <event event-type="pmc-last-change">
            <date iso-8601-date="2025-04-25 14:25:40.507">
              <day>25</day>
              <month>04</month>
              <year>2025</year>
            </date>
          </event>
        </pub-history>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1595849.pdf"/>
        <self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.nature.com/articles/s43018-020-0047-1"/>
        <abstract id="ABS1">
          <p id="P4">Alpelisib is a selective inhibitor of PI3Kα, shown to improve outcomes for <italic toggle="yes">PIK3CA</italic> mutant, hormone receptor positive (HR+) metastatic breast cancers (MBC) when combined with antiestrogen therapy. To uncover mechanisms of resistance, we conducted a detailed, longitudinal analysis of tumor and plasma circulating tumor DNA among such patients from a phase I/II trial combining alpelisib with an aromatase inhibitor (AI) (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/NCT01870505">NCT01870505</ext-link>). The trial’s primary objective was to establish safety with maculopapular rash emerging as the most common grade 3 adverse event (33%). Among 44 evaluable patients, the observed clinical benefit rate was 52%. Correlating genetic alterations with outcome, we identified loss-of-function <italic toggle="yes">PTEN</italic> mutations in 25% of patients with resistance. <italic toggle="yes">ESR1</italic> activating mutations also expanded in number and allele fraction during treatment and were associated with resistance. These data indicate that genomic alterations that mediate resistance to alpelisib or antiestrogen may promote disease progression and highlight <italic toggle="yes">PTEN</italic> loss as a recurrent mechanism of resistance to PI3Kα inhibition.</p>
        </abstract>
        <custom-meta-group>
          <custom-meta>
            <meta-name>pmc-status-qastatus</meta-name>
            <meta-value>0</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-live</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-embargo</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-status-released</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-open-access</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-olf</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-manuscript</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-legally-suppressed</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-pdf</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-has-supplement</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-pdf-only</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-suppress-copyright</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-real-version</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-is-scanned-article</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-preprint</meta-name>
            <meta-value>no</meta-value>
          </custom-meta>
          <custom-meta>
            <meta-name>pmc-prop-in-epmc</meta-name>
            <meta-value>yes</meta-value>
          </custom-meta>
        </custom-meta-group>
      </article-meta>
    </front>
  </article>
</pmc-articleset>
